Compare FLNC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | NTLA |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2021 | 2016 |
| Metric | FLNC | NTLA |
|---|---|---|
| Price | $21.13 | $13.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 23 |
| Target Price | $15.71 | ★ $20.02 |
| AVG Volume (30 Days) | ★ 9.8M | 6.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | $67,671,000.00 |
| Revenue This Year | $51.23 | N/A |
| Revenue Next Year | $21.30 | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $4.40 | $6.83 |
| 52 Week High | $33.51 | $28.24 |
| Indicator | FLNC | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 46.28 |
| Support Level | $13.05 | $11.06 |
| Resistance Level | $22.93 | $14.02 |
| Average True Range (ATR) | 2.00 | 1.14 |
| MACD | 1.07 | -0.03 |
| Stochastic Oscillator | 61.20 | 40.05 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.